5 Fluorouracil Preferentially Sensitizes Mutant KRAS Non-Small Cell Lung Carcinoma Cells to TRAIL-Induced Apoptosis

Mutations in the KRAS gene are very common in non–small cell lung cancer (NSCLC), but effective therapies targeting KRAS have yet to be developed. Interest in tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), a potent inducer of cell death, has increased following the observation that TRAIL can selectively kill a wide variety of human cancer cells without killing normal cells both in vitro and in xenograft models. However, results from clinical trials of TRAIL-based therapy are disappointingly modest at best and many have demonstrated a lack of therapeutic benefit.

Source: Molecular Oncology - June 19, 2015 Category: Cancer & Oncology Authors: Haizhen Wang, Tao Yang, Xiangwei Wu Source Type: research